By Daniel Molina, Shawn Hauser
Aug 30, 2024
With an upcoming legislative session that will consider medical cannabis expansion, hemp regulation, decriminalization, and other cannabis matters—we have our eyes on Texas! Read the first blog of our Texas series which covers updates on cannabis reform and decriminalization measures in cities like Dallas and Austin, which are set to be on the ballot in November.
By Jason Adelstone
Jul 24, 2024
Despite growing public support, EU nations face significant legal hurdles in establishing commercial marijuana markets due to international drug treaties and EU regulations. This Insights post highlights the various approaches toward cannabis reform taken by countries like Germany, Malta, the Netherlands, Switzerland, and the Czech Republic, and how this could potentially impact future cannabis policies in Europe.
By Jason Adelstone
May 20, 2024
In a recent House Committee meeting with DEA Administrator Anne Milgram, Rep. Andrew S. Clyde voiced his opposition to removing marijuana from Schedule I based on public safety reasons, but then contradicted himself by stating marijuana is “not as dangerous as some of the others we have talked about” (the meeting focused primarily on fentanyl’s harms to communities). This blog post addresses the false narratives and misconceptions that opponents of cannabis reform continue to promote.
By Michelle Bodian
May 17, 2024
This was a big week for hemp (as well as marijuana)! The proposed rules to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) were released and will be officially published in the federal register on May 21, 2024. Some of the language is relevant to hemp and hemp products. Additionally, the U.S. House of Representatives released draft text for the 2023 Farm Bill. Read this insight for key takeaways.
May 7, 2024
On May 8, Vicente’s director of economics and research, Andrew Livingston, is joining Rootwurks for a webinar to break down what it will mean for the cannabis industry now that the DEA is making moves to reclassify cannabis into schedule III—and what work for legalization remains to be done. Register now!
By Shawn Hauser
May 7, 2024
Vicente LLP partner Shawn Hauser argues in a new Marijuana Moment op-ed that the federal decision to reschedule cannabis is “a historic and critically important shift”—with the government “finally (and officially) recognizing the efficacy and safety of cannabis for medical use.”
May 3, 2024
Watch this special briefing featuring Vicente LLP leaders who have been deeply immersed in the federal scheduling issue, along with Mitzi Keating, a CPA and partner at Citrin Cooperman.
By Jason Adelstone
Apr 29, 2024
After listening to the House Oversight and Accountability Committee Hearing with the Commissioner of the FDA on April 11, one conclusion was reinforced—opponents of marijuana reform are misinformed and rely on misstating facts to support their position. Those against moving marijuana into schedule III are making their voices heard, but almost universally, those voices simply do not understand what schedule III would mean.
By Jason Adelstone
Mar 21, 2024
The International Narcotics Control Board (INCB) may be taking a more measured approach to cannabis. In their 2023 report, INCB used the word "may" when discussing potential inconsistencies between US state legalization and international treaties. This subtle shift in language suggests a more open-minded approach. This blog post explores the significance of this change in the report’s language and what it might mean for the future of global cannabis legalization.
By Jason Tarasek
Feb 2, 2024
Minnesota dispensaries could be a reality by summer! The OCM unveiled an ambitious plan to speed up the launch, proposing temporary regulations and licensing reforms. Focusing on social equity, product availability, and education, they are streamlining the process by removing initial premise requirements, local government involvement, and even suggesting a new social equity classification. Read this Insights post for the latest update on Minnesota’s cannabis business regulations.
By Jason Adelstone
Jan 30, 2024
On August 29, 2023, the Department of Health and Human Services (“HHS”) sent the Drug Enforcement Administration (“DEA”) its recommendation to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). Since then, the marijuana industry has waited in suspense for the DEA to make the final call as to what schedule marijuana will be placed. Read this Insights post that outlines the complex process of marijuana rescheduling in the US and outlines the key steps involved, from rule publication to review and final rule, emphasizing the critical role of stakeholder engagement in securing a Schedule III classification.
Oct 25, 2023
Andrew Livingston will present on cannabis supply and demand and Sally Kent Peebles will present on leveraging opportunities in new markets at MJBizCon this year. Read on for more information about their panels!